195 related articles for article (PubMed ID: 25489243)
1. Injectable long-acting systems for Radix Ophiopogonis polysaccharide based on mono-PEGylation and in situ formation of a PLGA depot.
Shi X; Lin X; Zheng X; Feng Y; Shen L
Int J Nanomedicine; 2014; 9():5555-63. PubMed ID: 25489243
[TBL] [Abstract][Full Text] [Related]
2. Delivery of radix ophiopogonis polysaccharide via sucrose acetateisobutyrate-based in situ forming systems alone or combined with itsmono-PEGylation.
Wang L; Zheng X; Wu F; Shen L; Lin X; Feng Y
Drug Deliv; 2018 Nov; 25(1):267-277. PubMed ID: 29334805
[TBL] [Abstract][Full Text] [Related]
3. Long-circulating delivery of bioactive polysaccharide from radix ophiopogonis by PEGylation.
Lin X; Wang ZJ; Huang F; Liang S; Shen L; Feng Y; Ruan KF
Int J Nanomedicine; 2011; 6():2865-72. PubMed ID: 22131832
[TBL] [Abstract][Full Text] [Related]
4. Injectable long-acting in situ forming systems for Radix Ophiopogonis polysaccharide.
Shi X; Lin X; Yao C; Shen L; Feng Y
Int J Biol Macromol; 2015 Jan; 72():553-9. PubMed ID: 25236608
[TBL] [Abstract][Full Text] [Related]
5. Mono-PEGylated radix ophiopogonis polysaccharide for the treatment of myocardial ischemia.
Sun G; Lin X; Shen L; Wu F; Xu D; Ruan K; Feng Y
Eur J Pharm Sci; 2013 Jul; 49(4):629-36. PubMed ID: 23727058
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol)-radix Ophiopogonis polysaccharide conjugates: preparation, characterization, pharmacokinetics and in vitro bioactivity.
Lin X; Wang S; Jiang Y; Wang ZJ; Sun GL; Xu DS; Feng Y; Shen L
Eur J Pharm Biopharm; 2010 Oct; 76(2):230-7. PubMed ID: 20633648
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of a long-circulating PEGylated Radix Ophiopogonis polysaccharide].
Wang ZJ; Lin X; Shen L; Feng Y; Xu DS; Ruan KF
Yao Xue Xue Bao; 2011 Oct; 46(10):1257-61. PubMed ID: 22242461
[TBL] [Abstract][Full Text] [Related]
8. Targeting delivery of Radix Ophiopogonis polysaccharide to ischemic/reperfused rat myocardium by long-circulating macromolecular and liposomal carriers.
Wang L; Yao C; Wu F; Lin X; Shen L; Feng Y
Int J Nanomedicine; 2015; 10():5729-37. PubMed ID: 26425081
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tissue distribution of a PEGylated Radix Ophiopogonis polysaccharide in mice with normal and ischemic myocardium.
Lin X; Wang ZJ; Wang S; Shen L; Feng Y; Ruan KF; Xu DS
Eur J Pharm Biopharm; 2011 Nov; 79(3):621-6. PubMed ID: 21784151
[TBL] [Abstract][Full Text] [Related]
10. Increased cardiac distribution of mono-PEGylated Radix Ophiopogonis polysaccharide in both myocardial infarction and ischemia/reperfusion rats.
Yao C; Shi X; Lin X; Shen L; Xu D; Feng Y
Int J Nanomedicine; 2015; 10():409-18. PubMed ID: 25609953
[TBL] [Abstract][Full Text] [Related]
11. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
12. PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co-glycolide).
Na DH; DeLuca PP
Pharm Res; 2005 May; 22(5):736-42. PubMed ID: 15906168
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene-/raloxifene-poly(ethylene glycol) conjugate-loaded microspheres: A novel strategy for drug delivery to bone forming cells.
Kavas A; Keskin D; Altunbaş K; Tezcaner A
Int J Pharm; 2016 Aug; 510(1):168-83. PubMed ID: 27343363
[TBL] [Abstract][Full Text] [Related]
14. Multi-arm histidine copolymer for controlled release of insulin from poly(lactide-co-glycolide) microsphere.
Park W; Kim D; Kang HC; Bae YH; Na K
Biomaterials; 2012 Dec; 33(34):8848-57. PubMed ID: 22959184
[TBL] [Abstract][Full Text] [Related]
15. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.
Na DH; Lee KC; DeLuca PP
Pharm Res; 2005 May; 22(5):743-9. PubMed ID: 15906169
[TBL] [Abstract][Full Text] [Related]
16. Tracking the in vivo release of bioactive NRG from PLGA and PEG-PLGA microparticles in infarcted hearts.
Pascual-Gil S; Simón-Yarza T; Garbayo E; Prosper F; Blanco-Prieto MJ
J Control Release; 2015 Dec; 220(Pt A):388-396. PubMed ID: 26546270
[TBL] [Abstract][Full Text] [Related]
17. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability.
Schoenhammer K; Petersen H; Guethlein F; Goepferich A
Int J Pharm; 2009 Apr; 371(1-2):33-9. PubMed ID: 19135512
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
[TBL] [Abstract][Full Text] [Related]
19. [Preparation and pharmacokinetic evaluation of long-acting injectable oily suspensions for ophiopogonis radix polysaccharide MDG-1].
Shi XL; Yao CX; Lin X; Shen L; Feng Y
Zhongguo Zhong Yao Za Zhi; 2014 Jul; 39(13):2489-94. PubMed ID: 25276969
[TBL] [Abstract][Full Text] [Related]
20. Investigation of Fragment Antibody Stability and Its Release Mechanism from Poly(Lactide-co-Glycolide)-Triacetin Depots for Sustained-Release Applications.
Chang DP; Garripelli VK; Rea J; Kelley R; Rajagopal K
J Pharm Sci; 2015 Oct; 104(10):3404-17. PubMed ID: 26099467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
